Daunorubicin, cytosine arabinoside and 6-thioguanine (DAT) combination chemotherapy for the treatment of acute non-lymphocytic leukemia.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D013866:Thioguanine / Q000008:administration & dosage / Q000009:adverse effects
D000970:Antineoplastic Agents; D003561:Cytarabine; D013866:Thioguanine; D003630:Daunorubicin